Literature DB >> 21310586

Attention deficit hyperactivity disorder (ADHD) in childhood epilepsy.

Colin J Reilly1.   

Abstract

ADHD and epilepsy common are both common childhood disorders and both can have significant negative consequences on a child's behavioural, learning, and social development. Both conditions can co-occur and population studies suggest that the prevalence of ADHD in childhood epilepsy is between 12 and 17%. The prevalence of epilepsy in ADHD is lower but it is not clear if the rate of epilepsy is higher in ADHD populations than in the general population. There is a higher occurrence of ADHD--Primarily Inattentive subtype in children with epilepsy and the reasons for this are not altogether clear but attention difficulties are very prevalent in childhood epilepsy. Seizure/epilepsy variables do not appear to be important correlates in most cases of ADHD in epilepsy although they may play a role in some cases. Individuals with both epilepsy and intellectual disability may be at higher risk for significant ADHD symptoms although screening and assessment in children with intellectual disability and epilepsy may be challenging. Children with epilepsy and ADHD are likely to be at higher risk for more negative outcomes in school and in terms of quality of life compared with children with epilepsy alone. Published studies on the treatment of ADHD in childhood epilepsy have focussed exclusively on the use of psychopharmacology and particularly methylphenidate. Although methylphenidate appears to be effective for some children with epilepsy the issue of whether it may lower seizure threshold continues to be debated. Children with epilepsy are at significant risk for ADHD and there is a need for more studies focussing on safe and efficacious interventions for symptoms of ADHD in this population.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21310586     DOI: 10.1016/j.ridd.2011.01.019

Source DB:  PubMed          Journal:  Res Dev Disabil        ISSN: 0891-4222


  8 in total

1.  Reliability of early cortical auditory gamma-band responses.

Authors:  Mackenzie C Cervenka; Piotr J Franaszczuk; Nathan E Crone; Bo Hong; Brian S Caffo; Paras Bhatt; Frederick A Lenz; Dana Boatman-Reich
Journal:  Clin Neurophysiol       Date:  2012-07-06       Impact factor: 3.708

Review 2.  Childhood epilepsy and autism spectrum disorders: psychiatric problems, phenotypic expression, and anticonvulsants.

Authors:  Sally J Robinson
Journal:  Neuropsychol Rev       Date:  2012-08-09       Impact factor: 7.444

3.  Prevalence of Epilepsy and Inter-Ictal Epileptiform Discharges in Children with Autism and Attention-Deficit Hyperactivity Disorder.

Authors:  B Anukirthiga; Devendra Mishra; Sanjay Pandey; Monica Juneja; Neetu Sharma
Journal:  Indian J Pediatr       Date:  2019-05-24       Impact factor: 1.967

4.  Attention deficit hyperactivity disorder (ADHD) in children with epilepsy.

Authors:  Man Wang; Qin Zhao; Huicong Kang; Suiqiang Zhu
Journal:  Ir J Med Sci       Date:  2019-06-11       Impact factor: 1.568

5.  [Formula: see text]Differences in memory functioning between children with attention-deficit/hyperactivity disorder and/or focal epilepsy.

Authors:  Sylvia E Lee; Michelle Y Kibby; Morris J Cohen; Lisa Stanford; Yong Park; Suzanne Strickland
Journal:  Child Neuropsychol       Date:  2015-07-08       Impact factor: 2.500

Review 6.  The Challenge of Pharmacotherapy in Children and Adolescents with Epilepsy-ADHD Comorbidity.

Authors:  Alberto Verrotti; Romina Moavero; Gianvito Panzarino; Claudia Di Paolantonio; Renata Rizzo; Paolo Curatolo
Journal:  Clin Drug Investig       Date:  2018-01       Impact factor: 2.859

7.  Mutation of Elfn1 in mice causes seizures and hyperactivity.

Authors:  Jackie Dolan; Kevin J Mitchell
Journal:  PLoS One       Date:  2013-11-27       Impact factor: 3.240

8.  Treatment of Children and Adolescents with Epilepsy with Atomoxetine.

Authors:  Kee Jeong Park; Hyunji Ahn; Mi-Sun Yum; Tae-Sung Ko; Hyo-Won Kim
Journal:  Psychiatry Investig       Date:  2020-04-17       Impact factor: 2.505

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.